Discontinued — last reported Q4 '24

Tax

Tax Reconciliation, Tax Credits

Vertex Pharmaceuticals Tax Reconciliation, Tax Credits remained flat by 0.0% to $0.26 in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 1615.0%, from $0.02 to $0.26. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement
SectionTax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ4 2024

How to read this metric

An increase indicates higher utilization of tax credits, which improves net profitability.

Detailed definition

Represents the percentage impact of various tax credits on the company's effective tax rate. These credits are typically...

Peer comparison

Standard line item in tax reconciliations; highly comparable across capital-intensive industries.

Metric ID: is_cop_tax_reconciliation_tax_credits

Historical Data

2 years
 FY'23FY'24
Value$0.06$1.03
YoY Change—>999%
Range$0.06 – $1.03
Avg YoY Growth>999%
Median YoY Growth>999%

Frequently Asked Questions

What is Vertex Pharmaceuticals's tax reconciliation, tax credits?
Vertex Pharmaceuticals (VRTX) reported tax reconciliation, tax credits of $0.26 in Q4 2024.
How has Vertex Pharmaceuticals's tax reconciliation, tax credits changed year-over-year?
Vertex Pharmaceuticals's tax reconciliation, tax credits increased by 1615.0% year-over-year, from $0.02 to $0.26.
What does tax reconciliation, tax credits mean?
The percentage point reduction in the effective tax rate resulting from government tax credits.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.